store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Valspodar (PSC 833) 是一种特异性的 P-糖蛋白抑制剂和MDR调节剂,常被用作化学增敏剂,可用于研究晚期上皮卵巢癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,890 | 现货 | ||
5 mg | ¥ 6,590 | 现货 | ||
10 mg | ¥ 8,890 | 现货 |
产品描述 | Valspodar (PSC 833) is a specific P-glycoprotein inhibitor and MDR regulator often used as a chemical sensitizer to study advanced epithelial ovarian cancer. |
靶点活性 | MDR cells:0.4μM |
体外活性 |
At concentrations up to 0.75 μg/mL, Valspodar (PSC 833) exhibits no cytotoxic effects. When Valspodar (0.25, 0.5, and 0.75 μg/mL) and DOX-L are introduced to DOX-resistant cells, the cell-killing efficacy of the MDR cell type significantly increases, particularly with the administration of Valspodar alongside DOX-L. The combination of Valspodar (0.5 and 0.75 μg/mL) with all concentrations of DOX is the most toxic, resulting in the death of more than 70% of the resistant cells [1]. Pretreatment with PSC833 reduces the IC50 value of NSC 279836 in MDA-MB-435mdr cells to 0.4±0.02 μM and almost completely reverses the resistance of MDR cells to NSC 279836 [2]. |
体内活性 |
Administered orally at a dose of 10 mg/kg, Valspodar exhibits minimal blood-cell partitioning, as indicated by its low mean blood-to-plasma ratio of approximately 0.52. Valspodar demonstrates characteristics of slow clearance and a large volume of distribution. Its properties include low hepatic extraction and wide distribution, akin to those observed in its structural analogue CsA [3]. Preadministration of PSC833 to mice increases NSC 279836 fluorescent intensity in MDR tumors to 94% of that observed in wild-type tumors [2]. |
别名 | PSC 833 |
分子量 | 1214.62 |
分子式 | C63H111N11O12 |
CAS No. | 121584-18-7 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (74.10 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 0.8233 mL | 4.1165 mL | 8.233 mL | 20.5826 mL |
5 mM | 0.1647 mL | 0.8233 mL | 1.6466 mL | 4.1165 mL | |
10 mM | 0.0823 mL | 0.4117 mL | 0.8233 mL | 2.0583 mL | |
20 mM | 0.0412 mL | 0.2058 mL | 0.4117 mL | 1.0291 mL | |
50 mM | 0.0165 mL | 0.0823 mL | 0.1647 mL | 0.4117 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Valspodar 121584-18-7 Membrane transporter/Ion channel Neuroscience P-gp PSC-833 PSC833 PSC 833 Inhibitor inhibitor inhibit